News
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
13don MSN
The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy. One day ...
Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...
Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.
Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results